Biophytis Faces Delay in Publishing 2025 Financial Statements

Biophytis, a biotechnology firm based in Paris and Cambridge, announced a delay in the publication of its 2025 financial statements. Originally expected sooner, the company is still finalizing year-end procedures and preparing for audits. This has made it impossible to meet the previously announced schedule.

The delay results from complex closing procedures and the need for thorough preparation before initiating official audits. Biophytis is in active discussions with its auditors to complete the audit as soon as feasible, while maintaining quality and compliance standards.

The company has also engaged in discussions with market authorities. It reminds stakeholders that failure to meet regulatory deadlines could lead to the suspension of its share trading on Euronext. Consequently, the annual shareholder meeting will also be postponed, with notice provided later.